Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations

伊马替尼 医学 内科学 髓系白血病 甲磺酸伊马替尼 费城染色体 蛋白激酶结构域 肿瘤科 酪氨酸激酶 达沙替尼 酪氨酸激酶抑制剂 癌症 遗传学 基因 生物 受体 染色体易位 突变体
作者
Naranie Shanmuganathan,David T. O. Yeung,Carol Wadham,Adelina Fernandes,Muneeza Maqsood,Nur Hezrin Shahrin,Verity A Saunders,Rosalie R. Kenyon,Ming Lin,John Toubia,Joe McConnell,Dominik C. Kaczorowski,David M. Ross,Agnes S. M. Yong,Lynette Chui Yen Chee,Jake Shortt,Nicholas Viiala,Jodi A. Braley,Chung Hoow Kok,Timothy P. Hughes
出处
期刊:Blood [Elsevier BV]
卷期号:146 (23): 2821-2832 被引量:23
标识
DOI:10.1182/blood.2025030259
摘要

ABSTRACT: Genomic profiling in patients with chronic-phase chronic myeloid leukemia (CP-CML) demonstrated somatic variants in blood cancer-related gene variants (CGVs) and rearrangements associated with the formation of the Philadelphia chromosome (Ph-associated rearrangements) at diagnosis, collectively termed additional genetic abnormalities (AGAs). AGAs had a negative impact on failure-free survival (FFS) and molecular response in imatinib-treated patients. We investigated whether treatment with more potent therapies could overcome the negative impact of AGAs at diagnosis. Targeted RNA-based next-generation sequencing was performed on diagnostic samples of 315 patients consecutively enrolled in 4 clinical trials of frontline potent tyrosine kinase inhibitors (TKIs) in CP-CML. AGAs were present in 34% of patients at diagnosis, including 20% harboring CGVs and 18% with Ph-associated rearrangements (4% had both). Although the negative impact of Ph-associated rearrangements was overcome by more potent inhibitors, patients with CGVs continued to experience inferior outcomes. This result was largely attributable to patients with ASXL1 variants, observed in 7% overall. Patients harboring ASXL1 variants also had inferior outcomes compared with those with wild-type ASXL1 in terms of 12-month major molecular response (55% vs 83%; P = .001), 2-year FFS (61% vs 91%; P < .001), and notably, the development of treatment-emergent BCR::ABL1 kinase domain mutations at 2 years (35% vs 1%; P < .001). In multivariable models, both CGVs and ASXL1 variants were predictors of each outcome. Treatment with frontline potent TKIs overcame the negative impact of Ph-associated rearrangements observed with frontline imatinib. However, inferior outcomes were still associated with the presence of CGVs. The acquisition of TKI-resistant BCR::ABL1 mutations was almost exclusively associated with mutated ASXL1 at diagnosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏的应助被向天一采纳,获得10
1秒前
1秒前
drt关闭了drt的文献求助
1秒前
星光不负赶路人完成签到,获得积分10
2秒前
wanchao发布了新的文献求助10
2秒前
Owen的应助被ally采纳,获得10
2秒前
Sun发布了新的文献求助40
3秒前
嘻嘻哈哈的应助被四方采纳,获得10
3秒前
smkyt完成签到,获得积分10
4秒前
知沐完成签到,获得积分10
4秒前
harlotte完成签到,获得积分10
4秒前
LW完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
6秒前
小羊完成签到 ,获得积分10
6秒前
羰醛完成签到,获得积分10
6秒前
天天快乐的应助被开心德地采纳,获得10
6秒前
7秒前
8秒前
扯纸大王完成签到,获得积分10
8秒前
8秒前
沉默的板凳完成签到,获得积分10
9秒前
9秒前
10秒前
小巧妙梦发布了新的文献求助10
10秒前
CXY发布了新的文献求助10
10秒前
梦璃完成签到 ,获得积分10
11秒前
11秒前
11秒前
共享精神的应助被ally采纳,获得10
11秒前
老年人发布了新的文献求助10
12秒前
12秒前
瘦瘦草丛发布了新的文献求助10
12秒前
云海完成签到,获得积分10
13秒前
称心学姐完成签到 ,获得积分10
13秒前
852的应助被00采纳,获得10
14秒前
14秒前
bkagyin的应助被开心德地采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187707
求助须知:如何正确求助?哪些是违规求助? 9575782
关于积分的说明 21843037
捐赠科研通 7785576
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2481986